News Summary
Valencia Technologies, a California-based medical device firm, has secured a strategic investment of up to $35 million to accelerate the commercialization of its eCoin® system. The FDA-approved device aims to treat urgency urinary incontinence. The company has also appointed James D. Surek as its new CEO to guide its growth. With support from Brooks Advisory Group, Valencia Technologies is positioned to enhance its market presence and operational effectiveness in the neuromodulation sector.
California – Valencia Technologies, a California-based medical device company, has secured a strategic investment of up to $35 million aimed at accelerating the commercialization of its flagship product, the eCoin® system. The investment is funded by Brooks Advisory Group, an affiliate of Brooks Management Group (BMG), an integral player in supporting the growth of the company.
The eCoin system, which received FDA approval in 2022, is the first and only FDA-approved subcutaneous implantable tibial nerve stimulator designed specifically for treating urgency urinary incontinence (UUI). This minimally invasive device, approximately the size of a coin, is implanted under the skin near the ankle. Once in place, it delivers periodic stimulation to the tibial nerve twice a week, significantly reducing episodes of UUI by at least 50% in 75% of patients after one year.
Alongside the investment, Valencia Technologies has appointed James D. Surek as its new CEO. Surek brings a wealth of experience in the medical device industry, having previously led successful initiatives that contributed to significant revenue growth across multiple companies. His leadership is expected to guide Valencia Technologies through its next phase of growth and product commercialization.
In addition to financial backing, Brooks Advisory Group will offer consulting services focusing on commercialization strategies, sales development, reimbursement processes, payor services, and financial planning. This comprehensive support aims to enhance Valencia Technologies’ market presence and operational effectiveness.
The management team at Valencia Technologies now includes Surek alongside key figures such as Dain Black, Ryan Brooks, and existing Board members Jeff Greiner and Don Hubbard. This team is well-positioned to leverage their expertise for the company’s advancement in the neuromodulation market.
James D. Surek has a notable track record in the medical device sector, having previously driven revenue growth of over $200 million within three years for Advanced Bionics, a company acquired by Boston Scientific for approximately $3 billion. He also successfully scaled the revenue of Entellus Medical from less than $1 million to over $70 million within four years, leading the company to an IPO during that time.
The eCoin device offers a streamlined approach to treating overactive bladder, providing patients a less invasive alternative compared to traditional medications or surgical interventions. The device minimizes the need for follow-up programming sessions and eliminates the necessity for weekly recharging, making it a convenient option for patients managing urgency urinary incontinence.
Physicians, including Dr. Jason Kim from Stony Brook Medicine, have recognized the eCoin system as an effective treatment alternative. They emphasize that it represents a significant advancement for patients suffering from overactive bladder symptoms, providing a balance of effectiveness and ease of use.
As Valencia Technologies prepares for the next steps in its commercialization strategy, the combination of substantial financial investment and strong leadership is anticipated to enhance its capabilities in the medical device field, particularly in the growing area of neuromodulation therapies.
With the backing of Brooks Advisory Group and the strategic appointment of James D. Surek, Valencia Technologies aims not only to establish its presence in the marketplace but also to improve the quality of life for patients dealing with debilitating urinary incontinence symptoms. The company’s ongoing commitment to innovation in medical devices places it at the forefront of solutions for patients seeking effective treatment options.
Deeper Dive: News & Info About This Topic
- PR Newswire: Valencia Technologies Announces Strategic Investment
- Wikipedia: Neuromodulation
- LA Business Journal: Avita Gets FDA Nod for Device
- Google Search: FDA Approval History
- Fortune: Fortune Global Forum on AI Integration
- Google Scholar: Medical Device Innovations
- Forbes: Singapore Billionaire Appointed President of Valencia Football Club
- Encyclopedia Britannica: Medical Devices
- Positively Osceola: Osceola County Advances Neocity Vision
- Google News: Medical Device Investments
Author: Anaheim Staff Writer
Anaheim Staff Writer The Anaheim Staff Writer represents the experienced team at HEREAnaheim.com, your go-to source for actionable local news and information in Anaheim, Orange County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as major conventions at the Anaheim Convention Center, including NAMM and VidCon, exciting games at Angel Stadium and Honda Center, and developments at Disneyland Resort Our coverage extends to key organizations like the Anaheim Chamber of Commerce and Visit Anaheim, plus leading businesses in hospitality, entertainment, and innovation that power the local economy As part of the broader HERE network, including HERECostaMesa.com, HEREHuntingtonBeach.com, HERESantaAna.com, and HERELosAngeles.com, we provide comprehensive, credible insights into Southern California's dynamic landscape.
